Want to see PALI full AI Analyst Report?
PALI Stock Chart & Stats
$2.40
-$0.36(-15.79%)
At close: 4:00 PM EST
$2.40
-$0.36(-15.79%)
Day’s Range― - ―
52-Week Range$0.53 - $2.86
Previous CloseN/A
Volume307.14K
Average Volume (3M)3.81M
Market Cap
$341.95M
Enterprise Value$172.87M
Total Cash (Recent Filing)$132.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Aug 25, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding173,579,670
10 Day Avg. Volume6,254,682
30 Day Avg. Volume3,810,744
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$10.40Price Target Upside333.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetNear-zero debt and a sizable equity base provide structural financial resilience for a clinical-stage biotech. This reduces insolvency risk, preserves flexibility to fund trials or bridge financing, and supports partnering/licensing negotiations over the next several quarters without immediate solvency pressure.
Approved Increase In Authorized SharesA larger pool of authorized shares is a durable governance tool enabling the company to raise equity, fund clinical development, and implement stock-based compensation without requiring frequent charter amendments. This structural flexibility supports multi-quarter financing planning for R&D programs.
Shareholder Support / Governance ContinuityBroad shareholder backing of directors, auditor ratification, and governance items indicates management and board continuity. Stable leadership and validated governance frameworks reduce execution and oversight risk for ongoing clinical programs and strategic partnerships over the medium term.
Bears Say
Minimal Revenue & Widening LossesSustained lack of operating revenue and large recurring losses are structural challenges for a clinical-stage biotech. Over 2–6 months this necessitates continued external capital, limits reinvestment capacity, and increases execution risk if funding or clinical milestones slip.
Persistent Negative Operating Cash FlowOngoing negative operating and free cash flow mean the business is not self-sustaining and will depend on capital markets or partners. This structural cash burn constrains long-term planning, risks program delays without financing, and increases the likelihood of dilution or onerous financing terms.
Dilution Risk From Equity Programs And Share IncreaseExpanded authorized shares and refreshed equity plans create clear pathways for future dilution to fund operations and incentivize staff. While enabling financing, this structural dilution risk can reduce per-share economic value for existing holders absent material progress in clinical milestones or revenue generation.
Palisade Bio News
PALI FAQ
What was Palisade Bio, Inc.’s price range in the past 12 months?
Palisade Bio, Inc. lowest stock price was $0.53 and its highest was $2.85 in the past 12 months.
What is Palisade Bio, Inc.’s market cap?
Palisade Bio, Inc.’s market cap is $341.95M.
When is Palisade Bio, Inc.’s upcoming earnings report date?
Palisade Bio, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 45 days.
How were Palisade Bio, Inc.’s earnings last quarter?
Palisade Bio, Inc. released its earnings results on May 12, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.007.
Is Palisade Bio, Inc. overvalued?
According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued.
Does Palisade Bio, Inc. pay dividends?
Palisade Bio, Inc. does not currently pay dividends.
What is Palisade Bio, Inc.’s EPS estimate?
Palisade Bio, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio, Inc. have?
Palisade Bio, Inc. has 173,579,670 shares outstanding.
What happened to Palisade Bio, Inc.’s price movement after its last earnings report?
Palisade Bio, Inc. reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went down -2.604%.
Which hedge fund is a major shareholder of Palisade Bio, Inc.?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.40 (333.33% Upside)
$10.40 (333.33% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $249.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
159.21%
12-Months-Change
Fundamentals
Return on Equity
-36.79%
Trailing 12-Months
Asset Growth
1527.78%
Trailing 12-Months
Company Description
Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$10.40
▲(333.33% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
2.25% Insiders
4.62% Mutual Funds
<0.01% Other Institutional Investors
88.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---